Garanto A - Search Results

1

Antisense RNA Therapeutics: A Brief Overview.

Arechavala-Gomeza V, Garanto A. Arechavala-Gomeza V, et al. Among authors: garanto a. Methods Mol Biol. 2022;2434:33-49. doi: 10.1007/978-1-0716-2010-6_2. Methods Mol Biol. 2022. PMID: 35213008 Free PMC article.

2

Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.

Gerard X, Garanto A, Rozet JM, Collin RW. Gerard X, et al. Among authors: garanto a. Adv Exp Med Biol. 2016;854:517-24. doi: 10.1007/978-3-319-17121-0_69. Adv Exp Med Biol. 2016. PMID: 26427454 Review.

3

Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.

Garanto A, Collin RWJ. Garanto A, et al. Methods Mol Biol. 2018;1715:61-78. doi: 10.1007/978-1-4939-7522-8_5. Methods Mol Biol. 2018. PMID: 29188506

4

Antisense Oligonucleotide-Based Splicing Correction in Individuals with Leber Congenital Amaurosis due to Compound Heterozygosity for the c.2991+1655A>G Mutation in CEP290.

Duijkers L, van den Born LI, Neidhardt J, Bax NM, Pierrache LHM, Klevering BJ, Collin RWJ, Garanto A. Duijkers L, et al. Among authors: garanto a. Int J Mol Sci. 2018 Mar 7;19(3):753. doi: 10.3390/ijms19030753. Int J Mol Sci. 2018. PMID: 29518907 Free PMC article.

5

Antisense Oligonucleotide-Based Splice Correction of a Deep-Intronic Mutation in CHM Underlying Choroideremia.

Garanto A, van der Velde-Visser SD, Cremers FPM, Collin RWJ. Garanto A, et al. Adv Exp Med Biol. 2018;1074:83-89. doi: 10.1007/978-3-319-75402-4_11. Adv Exp Med Biol. 2018. PMID: 29721931

6

Delivery of oligonucleotide-based therapeutics: challenges and opportunities.

Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V. Hammond SM, et al. Among authors: garanto a. EMBO Mol Med. 2021 Apr 9;13(4):e13243. doi: 10.15252/emmm.202013243. Epub 2021 Apr 6. EMBO Mol Med. 2021. PMID: 33821570 Free PMC article. Review.

7

Antisense Oligonucleotide-Based Rescue of Aberrant Splicing Defects Caused by 15 Pathogenic Variants in ABCA4.

Tomkiewicz TZ, Suárez-Herrera N, Cremers FPM, Collin RWJ, Garanto A. Tomkiewicz TZ, et al. Among authors: garanto a. Int J Mol Sci. 2021 Apr 28;22(9):4621. doi: 10.3390/ijms22094621. Int J Mol Sci. 2021. PMID: 33924840 Free PMC article.

8

Development and Use of Cellular Systems to Assess and Correct Splicing Defects.

Suárez-Herrera N, Tomkiewicz TZ, Garanto A, Collin RWJ. Suárez-Herrera N, et al. Among authors: garanto a. Methods Mol Biol. 2022;2434:145-165. doi: 10.1007/978-1-0716-2010-6_9. Methods Mol Biol. 2022. PMID: 35213015 Free PMC article.

9

Considerations for Generating Humanized Mouse Models to Test Efficacy of Antisense Oligonucleotides.

Vázquez-Domínguez I, Garanto A. Vázquez-Domínguez I, et al. Among authors: garanto a. Methods Mol Biol. 2022;2434:267-279. doi: 10.1007/978-1-0716-2010-6_18. Methods Mol Biol. 2022. PMID: 35213024 Free PMC article.

10

Delivery of Antisense Oligonucleotides to the Mouse Retina.

Garanto A. Garanto A. Methods Mol Biol. 2022;2434:321-332. doi: 10.1007/978-1-0716-2010-6_22. Methods Mol Biol. 2022. PMID: 35213028 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

69 results

Search Page